Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">TRANSMYOCARDIAL LASER REVASCULARIZATION</title><author><name sortKey="Horvath, Keith A" sort="Horvath, Keith A" uniqKey="Horvath K" first="Keith A." last="Horvath">Keith A. Horvath</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">18435649</idno><idno type="pmc">4224272</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224272</idno><idno type="RBID">PMC:4224272</idno><idno type="doi">10.1111/j.1540-8191.2008.00579.x</idno><date when="2008">2008</date><idno type="wicri:Area/Pmc/Corpus">000333</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000333</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">TRANSMYOCARDIAL LASER REVASCULARIZATION</title><author><name sortKey="Horvath, Keith A" sort="Horvath, Keith A" uniqKey="Horvath K" first="Keith A." last="Horvath">Keith A. Horvath</name></author></analytic><series><title level="j">Journal of cardiac surgery</title><idno type="ISSN">0886-0440</idno><idno type="eISSN">1540-8191</idno><imprint><date when="2008">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p id="P1">It has been almost a decade since transmyocardial laser revascularization (TMR) was approved for clinical use in the United States. The safety of TMR was demonstrated initially with non-randomized studies in which TMR was used as the only treatment for patients with severe angina. TMR efficacy was proven after multiple randomized controlled trials. These revealed significant angina relief compared to maximum medical therapy in patients with diffuse coronary disease not amenable to conventional revascularization. In light of these results, TMR has been used as an adjunct to coronary artery bypass grafting (CABG). By definition, patients treated with this combined therapy have more severe coronary disease and the co morbidities that are associated with end stage athorosclorosis. Combination CABG + TMR has resulted in symptomatic improvement without additional risk. The likely mechanism whereby TMR has provided benefit is the angiogenesis engendered by the laser-tissue interaction. Improved perfusion and concomitant improvement in myocardial function has been observed post TMR. Additional therapies to enhance the angiogenic response include combining TMR with stem cell based treatments which appear to be promising future endeavors.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<pmc-dir>properties manuscript</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-journal-id">8908809</journal-id><journal-id journal-id-type="pubmed-jr-id">2080</journal-id><journal-id journal-id-type="nlm-ta">J Card Surg</journal-id><journal-id journal-id-type="iso-abbrev">J Card Surg</journal-id><journal-title-group><journal-title>Journal of cardiac surgery</journal-title></journal-title-group><issn pub-type="ppub">0886-0440</issn><issn pub-type="epub">1540-8191</issn></journal-meta><article-meta><article-id pub-id-type="pmid">18435649</article-id><article-id pub-id-type="pmc">4224272</article-id><article-id pub-id-type="doi">10.1111/j.1540-8191.2008.00579.x</article-id><article-id pub-id-type="manuscript">NIHMS635881</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>TRANSMYOCARDIAL LASER REVASCULARIZATION</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Horvath</surname><given-names>Keith A.</given-names></name><degrees>MD</degrees><aff id="A1">Director, Cardiothoracic Surgery Research, National Institutes of Health / NHLBI, 10 Center Drive - MSC 1454, Building 10CRC - Room 6-5140, Bethesda, MD 20892, 301-451-7098, Fax: 301-480-1649,<email>khorvath@nih.gov</email></aff></contrib></contrib-group><pub-date pub-type="nihms-submitted"><day>3</day><month>11</month><year>2014</year></pub-date><pub-date pub-type="ppub"><season>May-Jun</season><year>2008</year></pub-date><pub-date pub-type="pmc-release"><day>07</day><month>11</month><year>2014</year></pub-date><volume>23</volume><issue>3</issue><fpage>266</fpage><lpage>276</lpage><pmc-comment>elocation-id from pubmed: 10.1111/j.1540-8191.2008.00579.x</pmc-comment>
<abstract><p id="P1">It has been almost a decade since transmyocardial laser revascularization (TMR) was approved for clinical use in the United States. The safety of TMR was demonstrated initially with non-randomized studies in which TMR was used as the only treatment for patients with severe angina. TMR efficacy was proven after multiple randomized controlled trials. These revealed significant angina relief compared to maximum medical therapy in patients with diffuse coronary disease not amenable to conventional revascularization. In light of these results, TMR has been used as an adjunct to coronary artery bypass grafting (CABG). By definition, patients treated with this combined therapy have more severe coronary disease and the co morbidities that are associated with end stage athorosclorosis. Combination CABG + TMR has resulted in symptomatic improvement without additional risk. The likely mechanism whereby TMR has provided benefit is the angiogenesis engendered by the laser-tissue interaction. Improved perfusion and concomitant improvement in myocardial function has been observed post TMR. Additional therapies to enhance the angiogenic response include combining TMR with stem cell based treatments which appear to be promising future endeavors.</p></abstract></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0003330 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0003330 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.21. |  |